Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking ...

Following Pfizer’s acquisition, Biohaven’s valuation skyrocketed under Vlad Coric. Find out why BHVN stock’s growth potential ...

Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

Four Colorado physicians are named in a lawsuit settlement involving pharmaceutical company Biohaven, which allegedly paid ...

周二，Deutsche Bank开始对Biohaven Pharmaceutical Holding (NYSE: BHVN )的股票进行跟踪，给予买入评级，目标价为65.00美元。分析师认为，首席执行官Vlad ...

The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...

The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.

subsidiary. Pfizer has agreed to pay $59,746,277.54, plus interest, to resolve allegations that the subsidiary, Biohaven Pharmaceutical Holding Company Ltd. (Biohaven), knowingly submitted or ...

The $59,746,277 settlement resolves a federal court case that Connecticut and 37 other states and Puerto Rico had joined against Biohaven Pharmaceutical Holding Company Ltd., a Pfizer-owned local ...